Cosentyx's Effects on Immunity and Vaccine Response
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can weaken vaccine responses, including to COVID-19 shots, but does not make vaccination unsafe for most patients.[1]
What Medical Guidelines Say
The CDC and rheumatology experts, including the American College of Rheumatology (ACR), do not list Cosentyx as a reason to avoid COVID-19 vaccines. Fully vaccinated patients on biologics like Cosentyx produce antibodies, though levels may be lower than in healthy people.[2][3] No increased risk of severe COVID-19 from vaccines has been reported in studies of immunocompromised groups.
Timing Considerations for Dosing
No mandatory hold on Cosentyx before vaccination. ACR suggests optional timing: vaccinate before starting Cosentyx if possible, or pause dosing 1-2 weeks before and resume 1-2 weeks after for optimal response. Real-world data shows similar COVID-19 protection regardless.[4]
Risks of Skipping or Delaying Vaccine
COVID-19 infection poses higher risks for Cosentyx users due to immunosuppression—infection rates are elevated, with severe cases more common. Vaccination cuts hospitalization risk by 80-90% even with muted responses.[5]
Patient Experiences and Studies
In trials like the COSENTYX COVID-19 registry, no vaccine-related safety signals emerged among thousands of users. Breakthrough infections occurred but mirrored unvaccinated rates. Rheumatology clinics report routine co-administration without issues.[6]
When to Talk to Your Doctor
Consult your rheumatologist for personalized advice, especially with comorbidities or prior infections. They weigh infection risk vs. flare risk from pausing Cosentyx.
[1]: Cosentyx Prescribing Information (Novartis)
[2]: CDC COVID-19 Vaccines for Immunocompromised
[3]: ACR COVID-19 Vaccine Guidance
[4]: Annals of Rheumatic Diseases: Biologics and Vaccine Timing
[5]: NEJM: Vaccine Efficacy in Immunosuppressed
[6]: Novartis COSENTYX Safety Data